Symptomatic neuroma
Symptomatic neuroma may develop after a nerve dissection following any trauma to a peripheral nerve, whether accidental or planned (i.e. surgery). Neuroma-induced neuropathic pain and morbidity seriously affect the patient’s daily life and socioeconomic functioning. The incidence of symptomatic neuromas after peripheral nerve injury is estimated to be 3-5%, however certain surgeries (e.g. autograft procedures, amputations) may have up to a 30% incidence rate.

There are several surgical procedures possible to treat symptomatic end-neuromas, but none are considered gold standard for both treatment and prevention. The most common procedure is surgical removal of the neuroma and surrounding scar tissue, and placing the proximal stump into an area subjected to minimal mechanical stimulation.

Covering the nerve stump
Covering the nerve stump with a cap of autologous material prevents both neuroma development and regeneration, but has its limitations.

- Suitable veins need to be available and sacrificed and the stability of the treatment depends upon consistent venous integrity (i.e. no vein collapse).
- Muscle capping is often performed as this tissue is easily available, however the recurrence of very painful sensory neumoa has been reported. Replacing the refreshed nerve end into bone is a technically demanding option.
- Use of vascularized flaps is technically very demanding and only considered in specific cases. Unfortunately, this way of pain treatment in amputation has an average of 2.8 re-operations and the surgeries have a failure rate of 10% or more.

Research on better fixation techniques and covering the nerve stump with synthetic material bypassing possible biocompatibility issues of animal derived materials led to the idea to develop NEUROCAP®, a nerve capping device for the treatment of neuromas. Its composition is based on the same synthetic polymers used in NEUROLAC® nerve guide for treatment of peripheral nerve lesions.

NEUROCAP®
Management Of Neuroma
NEUROCAP® is intended to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic end-neuroma.

NEUROCAP® is a tubular device with one open end and one closed end. Dislocation of the nerve stump is prevented by suturing the nerve end into the cap. A hole at the sealed end of the tube allows easy fixation of the nerve stump with a suture to the surrounding tissue. This allows an effective capping technique without the necessity of drilling a hole into bones, or sacrificing other tissue.

The application of NEUROCAP® and the available device dimensions are illustrated in figure 1 and table 1.

Figure 1: NEUROCAP® Product Application

Table 1: NEUROCAP® Product Description

<table>
<thead>
<tr>
<th>D (mm)</th>
<th>Catalogue number</th>
<th>Recommended Needle &amp; Suture size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5</td>
<td>NC01-015/03</td>
<td>• 7.0 or 6.0 Polypropylene with smallest needle possible</td>
</tr>
<tr>
<td>2.0</td>
<td>NC01-020/03</td>
<td>• Tapered needle: 3/8 (9 - 11 mm)</td>
</tr>
<tr>
<td>2.5</td>
<td>NC01-025/03</td>
<td>• Tapered needle: 3/8 (9 - 11 mm)</td>
</tr>
<tr>
<td>3.0</td>
<td>NC01-030/03</td>
<td>• Needle or with the smallest tapered needle</td>
</tr>
<tr>
<td>4.0</td>
<td>NC01-040/03</td>
<td>• 5.0 or 6.0 Polypropylene or mono-</td>
</tr>
<tr>
<td>5.0</td>
<td>NC01-050/03</td>
<td>• Filament with 11 mm tapered needle</td>
</tr>
<tr>
<td>6.0</td>
<td>NC01-060/03</td>
<td>• 5.0 or 6.0 polyamide/nylon with 13 mm</td>
</tr>
<tr>
<td>7.0</td>
<td>NC01-070/03</td>
<td>• Needle or with the smallest tapered</td>
</tr>
<tr>
<td>8.0</td>
<td>NC01-080/03</td>
<td>• Needle available</td>
</tr>
</tbody>
</table>

To prove effectiveness of performance of NEUROCAP®, Polyganics is engaged with several European hospitals in an open non-randomized clinical investigation called STOP NEUROMA Trial.

STOP NEUROMA Trial
This study is being conducted to obtain data on the clinical performance of NEUROCAP®s ability to isolate the nerve end, resulting in a reduction of pain as experienced from the symptomatic neuroma and the prevention of the reocurrence of a symptomatic neuroma. If you need more information please contact us through info@polyganics.com

NEUROCAP® is available in 1 unit per box. It is packed in a plastic tray and a Tyvek pouch and subsequently placed in a aluminum pouch. NEUROCAP® is transparent, indicated for single-use and should be stored in a dry, dark place between -18 °C (0 F) and 8 °C (46 F). The shelf life is at least 18 months.

NEUROCAP® is a class II device which obtained 510(k) clearance (K152684). NEUROCAP® is a class III device under CE 0344.